Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-158.78%
operating margin TTM
-166.31%
revenue TTM
1.54 Million
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -2.24 |
| peg ratio | -0.92 |
| price to book ratio | 1.27 |
| price to sales ratio | 3.25 |
| enterprise value multiple | -2.49 |
| price fair value | 1.27 |
profitability ratios | |
|---|---|
| gross profit margin | 38.76% |
| operating profit margin | -166.31% |
| pretax profit margin | -159.06% |
| net profit margin | -158.78% |
| return on assets | -43.94% |
| return on equity | -55.25% |
| return on capital employed | -53.45% |
liquidity ratios | |
|---|---|
| current ratio | 3.41 |
| quick ratio | 3.00 |
| cash ratio | 1.26 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 123.07 |
| operating cycle | 220.38 |
| days of payables outstanding | 74.35 |
| cash conversion cycle | 146.03 |
| receivables turnover | 3.75 |
| payables turnover | 4.91 |
| inventory turnover | 2.97 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.06 |
| debt equity ratio | 0.07 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.07 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -6.16 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.97 |
| cash per share | 0.83 |
| operating cash flow per share | -0.89 |
| free cash flow operating cash flow ratio | 1.09 |
| cash flow coverage ratios | -6.16 |
| short term coverage ratios | -44.38 |
| capital expenditure coverage ratio | -11.27 |
Frequently Asked Questions
When was the last time Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported earnings?
Iovance Biotherapeutics, Inc. (IOVA) published its most recent earnings results on 06-11-2025.
What is Iovance Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)'s trailing twelve months ROE is -55.25%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Iovance Biotherapeutics, Inc. (IOVA) currently has a ROA of -43.94%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IOVA's net profit margin stand at?
IOVA reported a profit margin of -158.78% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IOVA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.41 in the most recent quarter. The quick ratio stood at 3.00, with a Debt/Eq ratio of 0.07.